Comments
Actelion sticks to outlook for 2012
18.10.2012. | ZURICH (Reuters) - Europe's largest biotechnology company Actelion stuck to its 2012 guidance for core earnings growth in the mid-single digit range as nine month sales of its most important drug slid 4 percent....
